

# Pre-clinical development of SCB0020160, a Sirt6 agonist with a potent anti-cancer effect

SCBIO



ONCOLOGY	Preclinical
Product Type	Small Molecule
Indication	Solid cancer, Pancreatic Cancer
Target	Sirt6
MoA(Mechanism of Action)	Activation of anti-tumor mechanisms in solid cancers through activation of Sirt6 related signal pathways
Competitiveness	<ul style="list-style-type: none"> <li>• First in Class: Solid cancer including Pancreatic Cancer treatment using SCB002 is the first-in-class new drug, and its unrivaled market position is guaranteed</li> <li>• Possible to secure exclusive rights: It is possible to secure exclusive rights for a long period of time with new products.</li> <li>• Anti-cancer synergy effect: SCB002 was demonstrated for its synergistic effect with various conventional therapeutics.</li> </ul>
Development Stage	Preclinical
Route of Administration	Oral administration